The Medical Letter on Drugs and Therapeutics
Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia
The full article is available to subscribers Subscriber Login   

The FDA has approved an estradiol softgel vaginal insert (Imvexxy – TherapeuticsMD) for treatment of postmenopausal women with moderate to severe dyspareunia due to vulvovaginal atrophy (VVA). Imvexxy is the second estradiol vaginal insert to be approved in the US; Vagifem, an intravaginal tablet formulation, was the first.1 Vagifem and Imvexxy are both available in inserts containing 10 mcg of estradiol; Imvexxy is also available in a 4-mcg strength.

TREATMENT OF DYSPAREUNIA — VVA is caused by a loss of estrogen in postmenopausal women.2 Symptoms of VVA include vaginal dryness, vaginal irritation, and dyspareunia.3 Over-the-counter vaginal moisturizers (Replens, and others) and lubricants (K-Y, and others) may provide ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia
Article code: 1555b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian